HER2.taNK

N/A

Report date: 2022/09/06 18:12:16

Base Information

Drug NameHER2.taNK

Drug Alias NameCAR-natural killer cell therapy (NantKwest)Target-activated natural killer cells (NantKwest)taNK cells (NantKwest)HER2taNKHER2.taNK cell therapy +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionT lymphocyte replacementsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNantkwest Inc

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Frankfurt

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A